Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis.

which was reported at last year's ERS and showed that withdrawing the steroid component from triple therapy with LAMA/LABA/ICS had no impact on exacerbation rates in COPD. That trial was not ...

Asthma inhalers are hand-held devices that allow you to inhale a dose of medication to treat asthma symptoms. There are many types of asthma inhalers. They differ in whether they're used for quick ...

SecurityWeek’s 2024 ICS Cybersecurity Conference kicks off today at the InterContinental Hotel Buckhead Atlanta. With 80+ sessions over three days, the conference brings together hundreds of critical ...

The FDA has requested five large clinical trials to evaluate fixed-dose ICS–LABA products with the primary outcome of life-threatening asthma exacerbation or death. The results will not be ...

Welcome to the Institute for Communications Systems (ICS), home of the 5G/6G Innovation Centre (5G/6GIC), one of the largest and most renowned academic research centres in its field in Europe.

Current maintenance or controller treatments for COPD include tiotropoium, LAMA, LABA, LABA + ICS, LAMA + LABA, roflumilast, theophylline, and 'triple therapy' combining LAMA + LABA + ICS.

Glycopyrrolate is a LAMA (long-acting muscarinic antagonist) bronchodilator, and indacaterol is a LABA (long-acting beta2-agonist) bronchodilator. Glycopyrrolate and indacaterol work by relaxing the ...

Also known as a ICS-LABA-LAMA combination, CHF 5993 is the first such extra-fine fixed triple combination being developed for COPD, or chronic obstructive pulmonary disease. The treatment, now being ...

Combination medications may include inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) long- acting muscarinic antagonist (LAMA) and long-acting beta2-agonist (LABA) short acting beta2 ...